A study to evaluate immunogenicity and safety of GlaxoSmithKline (GSK)’s Infanrix hexa vaccine (DTPa-HBV-IPV/Hib) versus MCM Vaccine BV’s Vaxelis vaccine (DTaP5-HBV-IPV-Hib) in healthy infants and toddlers

Trial Identifier: 212645
Sponsor: GlaxoSmithKline
Start Date: May 2021
Primary Completion Date: July 2022
Study Completion Date: July 2022

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Germany Bramsche, Germany, 49565
Germany Erfurt, Germany, 99086
Germany Moenchengladbach, Germany, 41236
Germany, Bayern Rosenheim, Bayern, Germany, 83026
Germany, Bayern Schoenau am Koenigssee, Bayern, Germany, 83471
Germany, Brandenburg Leipzig, Brandenburg, Germany, 16269
Germany, Niedersachsen Wolfsburg, Niedersachsen, Germany, 38448
Germany, Nordrhein-Westfalen Huerth, Nordrhein-Westfalen, Germany, 50354
Germany, Nordrhein-Westfalen Moenchengladbach, Nordrhein-Westfalen, Germany, 41236
Germany, Rheinland-Pfalz Frankenthal, Rheinland-Pfalz, Germany, 67227
Italy Milano, Italy, 20122
Spain Badalona, Spain, 08916
Spain Boadilla del Monte (Madrid), Spain, 28660
Spain Leganes, Spain, 28911
Spain Lleida, Spain, 25198
Spain Madrid, Spain, 28046
Spain Madrid, Spain, 28040
Spain Santiago de Compostela, Spain, 15706
Spain Sevilla, Spain, 41013
Spain, Andalucia Malaga, Andalucia, Spain, 29004